{
    "2020-07-29": [
        [
            {
                "time": "",
                "original_text": "揭秘送转股293只除权以来股价上涨",
                "features": {
                    "keywords": [
                        "送转股",
                        "除权",
                        "股价上涨"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "股票市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "注意！益丰药房：高级管理人员减持计划完成 减持股份",
                "features": {
                    "keywords": [
                        "益丰药房",
                        "高级管理人员",
                        "减持计划",
                        "完成"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "益丰药房(603939.SH)：副总裁肖再祥累计减持3.15万股 减持计划实施完毕 减持股份",
                "features": {
                    "keywords": [
                        "益丰药房",
                        "副总裁",
                        "肖再祥",
                        "减持",
                        "3.15万股",
                        "计划完成"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【国元医药】美亚光电事件点评：口扫新产品获批，业绩新增量可期",
                "features": {
                    "keywords": [
                        "国元医药",
                        "美亚光电",
                        "口扫新产品",
                        "获批",
                        "业绩新增量"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}